CVS Health declares dividend as Cantor targets CVS Health stock at USD 110.00

Published on 10/02/2026 at 15:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 106.10 billion, up 7.30 percent year over year. CVS Health stock costs EUR 76.00 on October 2, 2026 after EUR 75.80.

Aquarellbild eines amerikanischen Gesundheitszentrums mit Bäumen und Parkplatz in Pastellfarben — CVS Health Corp. Aquarell-Illustration zeigt amerikanisches Gesundheitszentrum im sonnigen Vorort, ISIN US1266501006, Illustration mit AI erstellt.

CVS Health Corp. (ISIN US1266501006) was trading at EUR 76.00 at Lang & Schwarz on October 2, 2026 at 3:40 p.m. CEST, up 0.26 percent from the prior close of EUR 75.80. The latest corporate signal is a quarterly dividend declaration, while Cantor Fitzgerald reiterated an Overweight rating and a USD 110.00 price target on October 1, 2026.

Dividend sets the immediate income signal

According to CVS Health in its September 30, 2026 release, the board approved a quarterly dividend of USD 0.665 per share. The payment is scheduled for November 2, 2026, for shareholders of record on October 22, 2026.

The dividend announcement follows a stronger second quarter. Yahoo Finance reported that adjusted earnings per share reached USD 2.58 in the second quarter of 2026, up 42.50 percent year over year, while revenue rose 7.30 percent to USD 106.10 billion.

Guidance points to a broader recovery

The same second-quarter report showed adjusted operating income of USD 5.16 billion, up 35.40 percent year over year. CVS Health raised its fiscal 2026 adjusted earnings guidance to USD 7.90-8.10 per share from USD 7.30-7.50 and lifted its minimum revenue outlook to USD 414.00 billion from USD 405.00 billion.

For investors, the comparison between revenue growth and operating income growth is important: adjusted operating income expanded faster than sales in the second quarter. That pattern supports the recovery narrative, but the company still operates across insurance, pharmacy benefit management, pharmacies and health services, leaving medical costs and regulatory scrutiny as material operating variables.

Analyst target stays above the market

Investing.com reported on October 1, 2026 that Cantor Fitzgerald reiterated its Overweight rating and USD 110.00 target. The report also cited premiums up 19.00 percent and maximum out-of-pocket costs up 7.00 percent in the company specific Medicare Advantage discussion.

EUR 76.00 versus EUR 75.80

CVS Health stock was trading at EUR 76.00 at Lang & Schwarz on October 2, 2026 at 3:40 p.m. CEST, plus 0.26 percent versus the Lang & Schwarz prior close of EUR 75.80 on October 1, 2026. The primary listing is on the NYSE, where CVS was last at USD 86.48 at 9:54 a.m. EDT on October 2, 2026; the finance quote showed a market capitalization of USD 110.3 billion and a 52-week range of USD 69.51 to USD 110.68. The further course of trading is shown by the continuously updated real-time quote of CVS Health stock.